Gestational exposure to cocaine or pharmacologically related compounds: Effects on behavior and striatal dopamine receptors

Life Sciences

Volumn 63, Issue 22, 1998, Pages 2015-2022

  Stewart, Christopher W ^a,b   Scalzo, Frank M ^b   Valentine, Jack ^b   Holson, R Robert ^a   Ali, Syed F ^a,b   Slikker Jr , William ^a,b  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Behavior; Monoamines; Prenatal cocaine exposure; Quinpirole; Reuptake blockade

Indexed keywords

COCAINE; DOPAMINE 2 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN DEVELOPMENT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG ABUSE; FEMALE; NEUROTOXICITY; NONHUMAN; PRENATAL EXPOSURE; RAT;

EID: 0032561434     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00479-2     Document Type: Article

References (21)

1. 1. K.A. BENSON, S.F. ALI and M.C. WILSON, Ann. N.Y. Acad. Sci. 801, 289-300 (1996).
2. 2. J.J. BYRNES, G.A. PRITCHARD, J.M. KOFF and L.G. MILLER, Neuropharm. 32, 721-723 (1993).
3. 3. A. DE BARTOLOMEIS, M.C. AUSTIN, G.A. GOODWIN, L.P. SPEAR, D. PICKAR and J.N. CRAWLEY, Molec. Brain Res. 21, 321-330 (1994).
4. 4. D.L. DOW-EDWARDS, L.A. FREED and T.A. FICO, Dev. Brain Res. 57, 263-269 (1990).
5. 5. Y.K. FUNG, J.A. REED and Y.-S. LAU, Gen. Pharmac. 20, 689-693 (1989).
6. 6. J. GLOWINSKI and L.L. IVERSEN, J. Neurochem. 13, 655-669 (1966).
7. 7. M.B. HENDERSON, M.M. MCCONNAUGHEY and B.A. MCMILLEN, Brain Res. Bull. 26, 941-945 (1991).
8. 8. C.J. HEYSER, G.A. GOODWIN, C.A. MOODY and L.P. SPEAR, Pharm. Biochem. Behav. 42, 169-173 (1992).
9. 9. C.J. HEYSER, J.S. MILLER, N.E. SPEAR and L.P. SPEAR, Neurotox. Teratol. 14, 57-64 (1992).
10. 10. C.J. HEYSER, N.E. SPEAR and L.P. SPEAR, Behav. Neurosci. 106, 837-845 (1992).
11. 11. D.E. HUTCHINGS, T.A. FICO and D.L. DOW-EDWARDS, Neurotoxicol Teratol. 11, 65-69 (1989).
12. 12. B.K. KOE, J. Pharmcol. Exp. Ther. 199(3), 649-661 (1976).
13. 13. J.M. KOFF and L.G. MILLER, Brain Res. Bull. 33, 223-224 (1994).
14. 14. D.B. MILLER and F.J. SEIDLER, Brain Res. Bull. 33, 79-182 (1994).
15. 15. C.A. MOODY, N.A. FRAMBES and L.P. SPEAR, Psychopharm. 108, 256-262 (1992).
16. 16. J.S. MEYER, J.D. SHERLOCK and N.R. MACDONALD, Neurotox. Teratol. 14, 183-189 (1992).
17. 17. J. PERIS, M. COLEMAN-HARDEE and W.J. MILLARD, Pharm. Biochem. Behav. 42, 509-515 (1992).
18. 18. F.M. SCALZO, S.F. ALI, N.A. FRAMBES and L.P. SPEAR, Pharmcol. Biochem. Behav. 37, 371-373 (1992).
19. 19. S.K. SOBRIAN, S.F. ALI, W. SLIKKER, Jr. and R.R. HOLSON, Molec. Neurobiol. 11, 121-143 (1995)
20. 20. S.K SOBRIAN, L.E. BURTON, N.L. ROBINSON, W.K. ASHE, H. JAMES, D.L. STOKES and L.M. TURNER, Pharm. Biochem. Behav. 35, 617-629 (1990).
21. 21. SPEAR, L.P., C.L. KIRSTEIN and N.A. FRAMBES, Annals N. Y. Acad. Sci. 562, 290-307 (1989).